TITLE

Bayer completes acquisition of U.S biologics manufacturing facility from Novartis

PUB. DATE
October 2007
SOURCE
Chemical Business;Oct2007, Vol. 21 Issue 10, p75
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the acquisition by Bayer of a biologics manufacturing facility in California from Novartis in October 2007. Under the deal, the drug Betaseron will be manufactured by Bayer, retain all employees involved in the production of the drug. Reportedly, Novartis has also transferred manufacturing responsibilities of Betaseron to Bayer Schering Pharma worth US$200 million. Bayer Schering Pharma will also continue to pay royalties to Novartis until the expiration of the original regulatory filing.
ACCESSION #
27555647

 

Related Articles

  • Bayer Schering job cuts. William, Dede; Gibson, Jane // ICIS Chemical Business Americas;3/5/2007, Vol. 271 Issue 9, p13 

    This article reports that Schering is set to cut 950 jobs at its headquarters in Berlin, Germany by 2009. Werner Wenning, Bayer chairman, said the move is due to the merger between the pharmaceutical activities of Schering and Bayer. Wenning, who is also chairman of Bayer Schering Pharma's...

  • New step for Bayer Schering.  // R&D Magazine;Jan2007, Vol. 49 Issue 1, p12 

    The article reports that Schering has been renamed to Bayer Schering Pharma AG following its acquisition by Bayer AG in July 2006. According to Werner Wenning, Bayer AG management board chairman, the firm is focusing on the next steps. Bayer Schering Pharma AG together with Bayer's...

  • Bayer Acquires Facility from Novartis.  // BioPharm International;Nov2007, Vol. 20 Issue 11, p10 

    The article reports on the acquisition of Novartis AG's biologics manufacturing facility by Bayer Schering Pharma AG in the U.S. It relates that the facility will be used by the company to manufacture its multiple sclerosis drug Betaseron. In addition, the company will also extend support to...

  • Bayer acquires manufacturing facility from Novartis.  // PharmaWatch: Biotechnology;Nov2007, Vol. 6 Issue 11, p25 

    The article reports that Bayer Schering Pharma AG has purchased a manufacturing facility from Novartis AG in Emeryville, California. This move is part of a deal to acquire the rights to multiple sclerosis drug Betaseron. Bayer Schering will manufacture and retain full control of all...

  • Schering and Bayer seal drug ownership agreement. Chynoweth, Emma // ICIS Chemical Business;4/2/2007, Vol. 2 Issue 60, p33 

    This article reports that Bayer Schering Pharma and Novartis have settled a dispute over U.S. production of the interferon-based multiple sclerosis treatment Betaseron, sold in the U.S. as Betaferon. The deal sees Bayer Schering Pharma acquiring most of Novartis' Emeryville, California, site,...

  • CNS News Round-Up.  // PharmaWatch: Monthly Review;Nov2007, Vol. 6 Issue 11, p12 

    The article offers updates on treatments for central nervous system diseases. Bayer Schering Pharma AG has acquired a biologics manufacturing facility of Novartis AG. Alexza Pharmaceuticals Inc. will begin the Phase III clinical trial of its staccato loxapine, a treatment for acute agitation....

  • OncoMed's Wnt Deal Adds $40M Up Front.  // Bioworld Week;6/21/2010, Vol. 18 Issue 25, p5 

    The article reports that Redwood City, California-based OncoMed Pharmaceuticals Inc. secured a 40 million-worth early stage deal with Berlin's Bayer Schering Pharma AG to develop a drug targeting the Wnt signaling pathway.

  • Direvo Antibodies, Proteases Moving to Bayer Pipeline. Hollingsworth, Catherine // BioWorld Today;9/17/2008, Vol. 19 Issue 181, p1 

    The article reports on the acquisition of Direvo Biotech AG by Bayer HealthCare AG in September 2008. The €210 million deal will reportedly allow Bayer Healthcare to strengthen its biologicals research in the Bayer Schering Pharma AG division. It offers information on the protein...

  • European pharma consolidation generates quality spinoffs. Sheridan, Cormac // Nature Biotechnology;Dec2006, Vol. 24 Issue 12, p1458 

    The article focuses on the consolidation and acquisition of European pharmaceutical companies. The article discuses that Berlin based Schering company and two German companies are acquired by Bayer Healthcare, Germany, to establish Bayer-Schering Pharma. And the establishment will concentrate on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics